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Background
Pharmacokinetic interaction between Vinca alkaloids and
antiretrovirals has been widely demonstrated, even though
its clinical relevance is still debated. The incidence of
Hodgkin’s lymphoma appears to be rising in HIV-infected
people, and vinblastine - containing chemotherapy regi-
mens are widely recommended in these pts.
Purpose of the study
To evaluate the clinical interaction between HAART
regimens and vinblastine in HIV-infected patients with
HL.
Methods
Clinical charts of all HIV-infected patients followed at
our center with a diagnosis of HL were reviewed. Differ-
ences in group proportions were assessed using 2 test.
One way ANOVA test was used was to test for differ-
ences among independent groups. Potential risk factors
for WHO III-IV neutropenia were analysed by step for-
ward logistic regression analysis. The Hosmer and
Lemeshow goodness-of-fit test was used to assess model
fit. Statistical analysis was performed using the software
program Intercooled Stata .
Summary of results
From June 2002 to July 2009 sixteen patients with HL
were concomitantly treated with vinblastine-containing
regimens (ABVD or Stanford V) and HAART, supported
by G-CSF administration. (M/F: 11/5; median CD4 cell
count: 189/µl , IQR 15-459; median HIV-RNA 5.8 log10
copies/ml, IQR 2.9-6.9 ; bone marrow was involved in 50%
of cases. 43% of pts were in HL stage IV. 5 out of 16 pts
were on PI/r, 2 on unboosted-PI, 7 on NNRTI (6 EFV and
1 NVP) and 2 on raltegravir. Mean nadir neutrophil count
(+SD) for all cycles of PCT on the same HAART regimens
were 0.218+0.343x10
6/L for patients taking regimens con-
taining PI/r, 0.375+0.078x 10
6/L in patients taking PI-
unboosted and 1.560+715 x10
6/L in patients on non PI-
based regimens (P<0.001). After controlling for CD4 cell
count < 200/µl, use of zidovudine and bone marrow invol-
vement, the use of PIs were more likely to be associated
with severe grade III-IV neutropenia (OR, 34.3, 95%CI
1.9-602.4; P = 0.02; McFadden R2:0.50). The mean nadir
neutrophils count was 1.350x10
6/L (+SD 0.800) in patients
not taking RTV, 0.850x10
6/L (+SD 0.091) in patients tak-
ing 100 mg of RTV, and 0.047x106/L(+SD 0.050) in those
taking 200 mg of RTV as boosting, respectively.
Conclusions
The concomitant administration of vinblastine-contain-
ing chemotherapy regimens with PIs can lead to higher
levels of neutropenia and in this set of patients HAART
regimens containing different classes of drugs (NNRTI,
integrase inhibitors) are more advisable.
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